GLP-1 Therapies: Reducing Obesity and Healthcare Costs

This presentation explores the rising concern of obesity and its economic impact, highlighting annual costs surpassing $425 billion in the U.S. It introduces GLP-1 receptor agonists as an effective solution for weight management, supported by clinical trials showing significant results and improved adherence. The cost implications of GLP-1 usage suggest long-term healthcare savings despite initial investments, with market competition lowering costs. Safety concerns are addressed through...